Severity
Low
FDA Drug recall · Reported May 8, 2013
Subpotent Drug: Product did not conform to the 18-month stability test specification for active Free Benzocaine.
Reckitt Benckiser Inc recalled Cherry Cepacol Sore Throat Lozenges, Benzocaine 15 mg | Menthol 3.6 mg, a)16-count, NDC 6… - a low-severity action.
Cherry Cepacol Sore Throat Lozenges, Benzocaine 15 mg | Menthol 3.6 mg, a)16-count, NDC 6… was recalled by Reckitt Benckiser Inc in May 8, 2013. Reason: Subpotent Drug: Product did not conform to the 18-month stability test specification for active Free Benzoca…. Check the official notice for the remedy. Verify recall #D-310-2013 with the FDA Drug before acting.
The recall
Reckitt Benckiser Inc issued this low-severity FDA Drug recall-Subpotent Drug: Product did not conform to the 18-month stability test specification for active Free Benzoca….
Sourced from official FDA Drug enforcement records. Verify recall #D-310-2013 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-310-2013) was formally reported on May 8, 2013, with the manufacturer initiating the action on March 18, 2013. It is classified under Low severity (Class III), with a current status of Terminated. Reckitt Benckiser Inc is listed as the recalling firm, operating out of Parsippany, NJ. Federal records list the affected scope as 27,718 cases 16 count and 7,551 cases 576 count.
The documented reason for this recall is: Subpotent Drug: Product did not conform to the 18-month stability test specification for active Free Benzocaine. Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
27,718 cases 16 count and 7,551 cases 576 count
Related Recalls
6
5 from same agency
Cherry Cepacol Sore Throat Lozenges, Benzocaine 15 mg | Menthol 3.6 mg, a)16-count, NDC 63824-711-16 b) Institutional Size, 576-count, NDC 63824-711-98, OTC, Dist. by: Reckitt Benckiser, Parsippany, NJ 07054
Subpotent Drug: Product did not conform to the 18-month stability test specification for active Free Benzocaine.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-310-2013 |
| Date reported | May 8, 2013 |
| Date initiated | March 18, 2013 |
| Recalling firm | Reckitt Benckiser Inc |
| Firm location | Parsippany, NJ |
| Affected scope | 27,718 cases 16 count and 7,551 cases 576 count |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported May 8, 2013. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.